A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer
A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of MEDI4736 in Combination With Tremelimumab in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 4L6
- Research Site
-
Toronto, Ontario, Canada, M5G 2M9
- Research Site
-
-
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- Research Site
-
-
California
-
La Jolla, California, United States, 92093
- Research Site
-
Los Angeles, California, United States, 90025
- Research Site
-
Los Angeles, California, United States, 90095
- Research Site
-
San Francisco, California, United States, 94143
- Research Site
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Research Site
-
-
Florida
-
Orlando, Florida, United States, 32806
- Research Site
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Research Site
-
-
Kansas
-
Fairway, Kansas, United States, 66205
- Research Site
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Research Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Research Site
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Research Site
-
-
New York
-
New York, New York, United States, 10016
- Research Site
-
New York, New York, United States, 10065
- Research Site
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Research Site
-
-
South Carolina
-
Greenville, South Carolina, United States, 29605
- Research Site
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Research Site
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects
- 18 years and older
- Histologically or cytologically confirmed recurrent or metastatic squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx) that is incurable by local therapy.
- Subjects who are treatment-naive or pretreated (prior anti-PD-1 or anti-PD-L1 required) in the recurrent/metastatic setting.
- Subject eligibility will be based on PD-L1 expression as determined by a specified IHC assay.
Exclusion Criteria:
- Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment, receipt of last dose of an approved anticancer therapy within 21 days
- Concurrent or prior use of immunosuppressive medication within 14 days
- Active or prior documented autoimmune or inflammatory disease within 3 years with some exceptions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: MEDI4736 + tremelimumab
|
MEDI4736 will be administered by IV infusion in combination with tremelimumab.
Tremelimumab will be administered by IV infusion in combination with MEDI4736.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from Baseline in laboratory evaluations
Time Frame: Screening through 3 months after the last dose of study medication
|
Screening through 3 months after the last dose of study medication
|
|
Change from Baseline in vital signs
Time Frame: Screening through 3 months after the last dose of study medication
|
Screening through 3 months after the last dose of study medication
|
|
Number of subjects reporting adverse events
Time Frame: Screening through 3 months after the last dose of study medication
|
Screening through 3 months after the last dose of study medication
|
|
Number of subjects reporting serious adverse events
Time Frame: Screening through 3 months after the last dose of study medication
|
Screening through 3 months after the last dose of study medication
|
|
Number of subjects experiencing dose-limiting toxicities
Time Frame: First dose of study medications through 4 weeks after the first dose of study medication
|
First dose of study medications through 4 weeks after the first dose of study medication
|
|
Change from Baseline in electrocardiograms
Time Frame: Screening through 3 months through last dose of study medication
|
Screening through 3 months through last dose of study medication
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Individual MEDI4736 concentrations
Time Frame: First dose of MEDI4736 through 3 months after the last dose of study medication
|
First dose of MEDI4736 through 3 months after the last dose of study medication
|
|
Individual tremelimumab concentrations
Time Frame: First dose of tremelimumab through 3 months after the last dose of study medication
|
First dose of tremelimumab through 3 months after the last dose of study medication
|
|
MEDI4736 area under the concentration-curve
Time Frame: First dose of MEDI4736 through 3 months after the last dose of study medication
|
First dose of MEDI4736 through 3 months after the last dose of study medication
|
|
Objective Response Rate
Time Frame: Screening through 5 years after the last subject receives the first dose of study medication
|
Screening through 5 years after the last subject receives the first dose of study medication
|
|
Number of subjects that develop changes in detectable antidrug antibodies to MEDI4736
Time Frame: First dose of MEDI4736 through 6 months after the last dose of study medication
|
First dose of MEDI4736 through 6 months after the last dose of study medication
|
|
Disease Control Rate
Time Frame: Screening through 5 years after the last subject receives the first dose of study medication
|
Screening through 5 years after the last subject receives the first dose of study medication
|
|
Duration of Response
Time Frame: Screening through 5 years after the last subject receives the first dose of study medication
|
Screening through 5 years after the last subject receives the first dose of study medication
|
|
Progression Free Survival
Time Frame: Screening through 5 years after the last subject receives the first dose of study medication
|
Screening through 5 years after the last subject receives the first dose of study medication
|
|
Overall Survival
Time Frame: Screening through 5 years after the last subject receives the first dose of study medication
|
Screening through 5 years after the last subject receives the first dose of study medication
|
|
Tremelimumab area under the concentration-curve
Time Frame: First dose of tremelimumb through 3 months after the last dose of study medication
|
First dose of tremelimumb through 3 months after the last dose of study medication
|
|
Number of subjects that develop changes in detectable antidrug antibodies to tremelimumab
Time Frame: First dose of tremelimumab through 6 months after the last dose of study medication
|
First dose of tremelimumab through 6 months after the last dose of study medication
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Biomarkers
Time Frame: Screening through 3 months after the last patient receives the first dose of study medication
|
Evaluate biomarkers that may correlate with clinical activity of MEDI4736 monotherapy and in combination with tremelimumab
|
Screening through 3 months after the last patient receives the first dose of study medication
|
|
Change from Baseline in Patient-Reported Outcomes
Time Frame: Screening through 5 years after the last patient receives the first dose of study medication
|
Screening through 5 years after the last patient receives the first dose of study medication
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Head and Neck Neoplasms
- Neoplasms, Squamous Cell
- Carcinoma
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Durvalumab
- Tremelimumab
Other Study ID Numbers
Other Study ID Numbers
- D4190C00011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.